UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

_______________________________

FORM 8-K

_______________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) ~~of the Securities Exchange Act of 1934~~

~~Date~~ of ~~Report~~the ~~(Date~~Securities ofExchange ~~Earliest~~Act ~~Event~~of ~~Reported): March 6, 2024~~1934

~~_______________________________~~Date of Report (Date of Earliest Event Reported): March 19, 2024

Endo International plc

(Exact name of registrant as specified in its charter)

_______________________________

Ireland

001-36326

68-0683755

(State or other jurisdiction

of incorporation)

(Commission
File Number)

(IRS Employer

Identification No.)

Ireland		001-36326	68-0683755
First Floor, Minerva House, Simmonscourt RoadBallsbridge, Dublin 4, Ireland	Not Applicable
(State or other jurisdictionof incorporation)		(Commission File Number)	(IRS EmployerIdentification No.)
(Address of principal executive offices)	(Zip Code)

First Floor, Minerva House, Simmonscourt Road
Ballsbridge, Dublin 4,	Ireland	Not Applicable
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code 011-353-1-268-2000

Registrant's telephone number, including area code 011-353-1-268-2000

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: None (1)

(1) On August 26, 2022, Endo International plc’s ordinary shares, which previously traded on the Nasdaq Global Select Market under the symbol ENDP, began trading exclusively on the over-the-counter market under the symbol ENDPQ. On September 14, 2022, Nasdaq filed a Form 25-NSE with the ~~United~~U.S. ~~States~~ Securities and Exchange Commission (the “SEC”) and Endo International plc’s ordinary shares were subsequently delisted from the Nasdaq Global Select Market. On December 13, 2022, Endo International plc’s ordinary shares were deregistered under Section 12(b) of the Securities Exchange Act of 1934, as amended.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

☐ Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 21.0203. ~~Results~~ ofBankruptcy ~~Operations~~or ~~and Financial Condition.~~Receivership

OnAs ~~March~~previously disclosed, beginning on August 616, ~~2024~~2022, Endo International plc (the “Company,”) ~~“Endo~~and certain of its subsidiaries (collectively, the “Debtors”), orcommenced voluntary cases (the “weChapter 11 Cases”) ~~issued~~under anChapter ~~earnings~~11 ~~release~~of ~~announcing~~the ~~its~~United ~~financial~~States ~~results~~Bankruptcy ~~for~~Code (the ~~three~~“Bankruptcy ~~and~~Code”) ~~twelve~~in ~~months~~the ~~ended~~U.S. ~~December~~Bankruptcy ~~31,~~Court ~~2023~~for ~~and~~the ~~2022~~Southern District of New York (the “~~Earnings~~Bankruptcy ~~Release~~Court”). AThe ~~copy~~Chapter of11 Cases are being jointly administered under the ~~Earnings~~caption ~~Release~~In isre ~~attached~~Endo asInternational ~~Exhibit~~plc, 99et al.1, ~~hereto~~Case ~~and~~No. 22-22549 is(JLG). ~~incorporated~~On ~~herein~~December 19, by2023, ~~reference~~the Debtors filed a Joint Chapter 11 Plan of Reorganization (as amended, the “Plan”) in the Bankruptcy Court.

~~The~~On Company utilizes certain financial measures that are not prescribed by or prepared in accordance with accounting principles generally accepted in the U.S. (“GAAP”). The Company utilizes these financial measuresMarch 22, ~~commonly referred to as “non-GAAP~~2024,” asthe ~~supplements~~Bankruptcy toCourt ~~financial~~entered ~~measures~~an ~~determined~~order inconfirming ~~accordance~~and ~~with~~approving ~~GAAP when evaluating~~ the ~~Company’s~~fourth ~~operating~~amended ~~performance~~version ~~and~~of the ~~Company~~Plan, ~~believes~~which ~~that~~was ~~they~~filed ~~will~~on beMarch 18, ~~used~~2024 ~~by certain investors to measure~~ (the ~~Company’s~~“Confirmation ~~operating results~~Order”). The ~~Company~~Debtors ~~believes~~expect that ~~presenting~~the ~~these~~effective ~~non-GAAP~~date ~~financial~~of ~~measures~~the ~~provides~~Plan ~~useful information about~~ (the ~~Company’s~~“Effective ~~performance~~Date”) ~~across~~will ~~reporting~~occur ~~periods~~once onall aconditions ~~consistent~~precedent ~~basis by excluding certain items, which may be favorable or unfavorable, pursuant~~ to the ~~procedure~~Plan ~~described~~have inbeen ~~the~~satisfied ~~succeeding~~or ~~paragraph~~waived.

~~The~~Summary ~~initial identification and review~~ of the adjustments necessary to arrive at these non-GAAP financial measures are performed by a team of finance professionals that include the Chief Accounting Officer and segment finance leaders in accordance with the Company’s Adjusted Income Statement Policy, which is reviewed and approved annually by the Audit & Finance Committee of the Company’s Board of Directors. Company tax professionals review and determine the tax effect of adjusted pre-tax income at applicable tax rates and other tax adjustments as described below. Proposed adjustments, along with any items considered but excluded, are presented to the Chief Accounting Officer, Chief Executive Officer and/or the Chief Financial Officer for their consideration. In turn, the non-GAAP adjustments are presented to the Audit & Finance Committee on a quarterly basis as part of the Company’s standard procedures for preparation and review of the earnings release and other quarterly materials.Plan

~~These~~The ~~non-GAAP~~following ~~financial~~is ~~measures~~a ~~should~~summary beof ~~considered~~the ~~supplemental~~material toterms ~~and~~of ~~not~~the aPlan ~~substitute~~as ~~for~~approved ~~financial~~and ~~information~~confirmed ~~prepared~~by inthe ~~accordance~~Bankruptcy ~~with GAAP~~Court. ~~The~~This ~~Company’s~~summary ~~definition~~highlights only certain substantive provisions of ~~these~~the ~~non-GAAP~~Plan ~~financial~~and ~~measures~~is ~~may~~not ~~differ~~intended ~~from~~to ~~similarly~~be ~~titled~~a ~~measures~~complete ~~used~~description byof ~~others~~the Plan. ~~The~~This ~~definitions~~summary is qualified in its entirety by reference to the full text of the ~~most~~Confirmation ~~commonly~~Order, ~~used~~which ~~non-GAAP~~is ~~financial~~attached ~~measures~~hereto as Exhibit 99.1, and the Plan, which is attached hereto as Exhibit 2.1, both of which are ~~presented~~incorporated ~~below~~herein by reference.

~~Adjusted~~Among ~~income~~other ~~from~~things, ~~continuing~~the ~~operations~~Plan provides that:

~~Adjusted~~• ~~income~~first ~~from~~lien ~~continuing~~creditors ~~operations~~will ~~represents~~receive ~~Loss~~(1) ~~from~~96.3% ~~continuing~~of ~~operations~~equity ~~prepared~~(subject ~~in accordance with GAAP and adjusted for certain items. Adjustments~~ to ~~GAAP~~dilution ~~amounts~~under ~~may~~or ~~include,~~pursuant ~~but are not limited~~ to, ~~acquisition-related~~the ~~and~~rights ~~integration~~offerings ~~items, including transaction costs~~ and ~~changes in~~ the ~~fair~~backstop ~~value~~commitment ofagreements ~~contingent consideration; cost reduction~~ and ~~integration-related~~management ~~initiatives~~incentive ~~such~~plan) asin ~~separation~~a ~~benefits,~~new ~~continuity~~entity ~~payments,~~formed ~~other~~to ~~exit~~acquire ~~costs~~the ~~and certain costs associated with integrating an acquired company~~Company’s ~~operations;~~assets ~~certain~~(“New ~~amounts related to strategic review initiatives~~Endo”); ~~asset~~(2) ~~impairment~~an ~~charges;~~opportunity ~~amortization~~to ofparticipate ~~intangible~~in ~~assets;~~a ~~inventory~~rights ~~step-up recorded as part of our acquisitions~~offering; ~~litigation-related~~(3) ~~and other contingent matters;~~ certain ~~legal~~cash ~~costs~~payments; ~~gains~~and or(4) ~~losses from early termination of debt; debt modification costs; gains or losses from~~ the ~~sales~~proceeds of ~~businesses~~any ~~and~~exit ~~other assets; foreign currency gains or losses on intercompany~~ financing ~~arrangements~~; ~~reorganization items, net; the tax effect of adjusted pre-tax income at applicable tax rates and other tax adjustments; and certain other items.~~

~~Adjusted~~• ~~diluted~~second ~~net~~lien ~~income~~creditors ~~per~~and ~~share~~unsecured ~~from~~noteholders ~~continuing~~will ~~operations~~receive the remaining 3.7% of the equity (subject to dilution only by issuances under any management incentive plan, and ~~Adjusted~~subject ~~diluted~~to ~~weighted~~potential ~~average~~upward ~~shares~~adjustment as set forth in the Plan), $23.3 million in cash, certain proceeds of litigation claims and insurance rights and will have an opportunity to participate in a $160 million rights offering (which was subscribed in July 2023);

~~Adjusted~~• ~~diluted~~sub-classes ~~net~~of ~~income~~other ~~per~~non-opioid ~~share~~unsecured ~~from~~creditors ~~continuing~~(including ~~operations~~mesh ~~represents~~claimants, ~~Adjusted~~ranitidine ~~income~~claimants, and certain antitrust claimants) will receive from ~~continuing~~certain ~~operations~~sub-trusts ~~divided~~up byto ~~the~~approximately ~~number~~$26.7 million in cash and proceeds of ~~Adjusted~~certain ~~diluted~~litigation ~~weighted~~claims ~~average~~and ~~shares.~~insurance recoveries;

~~Both~~• ~~GAAP~~in ~~and~~connection ~~non-GAAP~~with ~~diluted~~the ~~Net~~resolution ~~income~~reached ~~(loss)~~with ~~per~~the ~~share~~US ~~data~~Department isof ~~computed~~Justice ~~based~~with onrespect ~~weighted~~to ~~average~~criminal, ~~shares~~civil ~~outstanding~~ and, iftax-related ~~there~~claims, isNew ~~net~~Endo ~~income~~will ~~from~~pay ~~continuing~~$364.9 ~~operations~~million ~~(rather~~over ~~than~~10 ~~net~~years, ~~loss)~~or ~~during~~$200 ~~the~~million ~~period,~~if the ~~dilutive~~obligation ~~impact~~is ofpaid ~~share~~in ~~equivalents~~full ~~outstanding~~on ~~during~~ the ~~period.~~Effective ~~Diluted~~Date, ~~weighted~~plus ~~average~~contingent ~~shares~~consideration ~~outstanding~~of ~~and~~$25 ~~Adjusted~~million ~~diluted~~in ~~weighted~~each ~~average~~of ~~shares~~2024 ~~outstanding~~through ~~are~~2028 ~~calculated~~(up onto ~~the~~$100 ~~same~~million ~~basis~~in ~~except~~aggregate) ~~for~~dependent ~~the~~on ~~net~~New ~~income~~Endo’s orEBITDA ~~loss~~exceeding ~~figure~~defined ~~used in determining whether to include such dilutive impact.~~baselines;

~~Adjusted~~• ~~gross~~opioid ~~margin~~claimants will receive distributions from certain trusts and sub-trusts as follows: $460 million in installments for state opioid claimants (subject to prepayment in the amount of approximately $274 million), $119.7 million in installments for several subclasses of private opioid claimants (subject to prepayment in the amount of approximately $90 million), up to $15 million for tribal opioid claimants (subject to prepayment in the amount of approximately $9 million) and up to approximately $11.4 million for future opioid claimants;

~~Adjusted~~• ~~gross~~opioid ~~margin~~claims ~~represents~~held ~~total~~by ~~revenues~~other ~~less~~claimants ~~cost~~will ofreceive ~~revenues~~certain ~~prepared~~other inrecoveries ~~accordance~~as ~~with~~set ~~GAAP~~forth ~~and~~in ~~adjusted for~~ the ~~items~~Plan, ~~enumerated~~including ~~above~~approximately ~~under~~$3 ~~the~~million ~~heading~~for ~~“Adjusted~~public ~~income~~school ~~from continuing operations~~districts,” toapproximately ~~the extent such items relate to cost of revenues~~$7.25 ~~Such~~million ~~items~~for ~~may~~Canadian ~~include~~provinces, ~~but~~and ~~are~~up ~~not limited~~ to, ~~cost reduction and integration-related initiatives such as separation benefits~~$200,000 ~~continuity~~for ~~payments,~~foreign ~~other~~holders ~~exit~~of ~~costs~~claims ~~and~~against certain ~~costs~~foreign ~~associated~~entities ~~with~~who ~~integrating~~file anproofs ~~acquired~~of ~~company’s~~claim ~~operations;~~against ~~certain~~us ~~amounts~~by ~~related~~a todate ~~strategic~~certain ~~review~~(but ~~initiatives;~~after ~~amortization~~the ofgeneral ~~intangible~~bar ~~assets~~date); ~~inventory step-up recorded as part of our acquisitions;~~ and ~~certain other items.~~

~~Adjusted~~• ~~operating~~existing ~~expenses~~equity interests in the Company will be canceled, extinguished, and discharged, subject to applicable law, and holders will not receive a distribution on account of their equity interests.

~~Adjusted~~Also, ~~operating expenses represent operating expenses prepared~~ in ~~accordance~~connection with ~~GAAP and adjusted for~~ the ~~items~~Plan, ~~enumerated~~New ~~above~~Endo ~~under~~expects ~~the heading “Adjusted income from continuing operations,”~~ to ~~the~~incur ~~extent~~indebtedness ~~such~~of ~~items~~up ~~relate~~ to ~~operating expenses~~$2.5 billion, ~~Such~~which ~~items~~ may ~~include,~~be ~~but are not limited to, acquisition-related and integration items, including transaction costs and changes~~ in the ~~fair~~form ~~value~~ of ~~contingent~~a ~~consideration;~~new ~~cost~~money ~~reduction~~syndicated ~~and~~debt ~~integration-related~~financing, ~~initiatives~~new ~~such~~first aslien ~~separation~~secured ~~benefits,~~takeback ~~continuity payments~~debt, ~~other~~or ~~exit~~a ~~costs~~combination ~~and certain costs associated with integrating an acquired company’s operations; certain amounts related to strategic review initiatives; asset impairment charges; amortization~~ of ~~intangible assets; inventory step-up recorded as part of our acquisitions; litigation-related and other contingent matters; certain legal costs; debt modification costs; and certain other items~~both.

~~Adjusted~~The ~~income~~Debtors’ ~~taxes~~emergence from bankruptcy is subject to, among other things, consummation of the restructuring transactions described above, certain regulatory approvals, and ~~Adjusted~~execution and implementation of the definitive documents. The Debtors expect to timely emerge from bankruptcy. The Company cautions that trading in the ordinary shares during the pendency of the Chapter 11 Cases is highly speculative and poses substantial risks. If the Plan becomes effective, ~~tax~~the ~~rate~~ordinary shares will be canceled, and therefore trading prices for the ordinary shares may bear little or no relationship to the actual recovery, if any, by holders of the ordinary shares in the Chapter 11 Cases.

~~Adjusted~~Item income taxes are calculated by tax effecting adjusted pre-tax income and permanent book-tax differences at the applicable effective tax rate that will be determined by reference to statutory tax rates in the relevant jurisdictions in which the Company operates8. ~~Adjusted income taxes include current and deferred income tax expense commensurate with the non-GAAP measure of profitability~~01. ~~Adjustments~~Other are then made for certain items relating to prior years and for tax planning actions that are expected to be distortive to the underlying effective tax rate and trend in the effective tax rate. The most directly comparable GAAP financial measure for Adjusted income taxes is Income tax expense, prepared in accordance with GAAP. The Adjusted effective tax rate represents the rate generated when dividing Adjusted income taxes by the amount of adjusted pre-tax income.Events

~~EBITDA~~On March 19, 2024, the Company issued a press release announcing the confirmation of the Plan, which is attached hereto as Exhibit 99.1 and ~~Adjusted~~incorporated ~~EBITDA~~herein by reference.

~~EBITDA~~Monthly ~~represents~~Operating ~~Net~~Reports income (loss) before Interest expense, net; Income tax expense; Depreciation; and Amortization, each prepared in accordance with GAAP. Adjusted EBITDA further adjusts EBITDA by excluding other (income) expense, net; share-based compensation; acquisition-related and integration items, including transaction costs and changes in the fair value of contingent consideration; cost reduction and integration-related initiatives such as separation benefits, continuity payments, other exit costs and certain costs associated with integrating an acquired company’s operations; certain amounts related to strategic review initiatives; asset impairment charges; inventory step-up recorded as part of our acquisitions; litigation-related and other contingent matters; certain legal costs; debt modification costs; reorganization items, net; discontinued operations, net of tax; and certain other items.

~~The~~On ~~Company’s~~March 20, ~~Adjusted~~2024, ~~income~~each ~~from~~of ~~continuing~~the ~~operations,~~Debtors ~~Adjusted~~filed ~~diluted~~monthly ~~net~~operating ~~income~~reports ~~per~~(the“Monthly ~~share~~Operating ~~from~~Reports”) ~~continuing~~with ~~operations~~the Bankruptcy Court for the month ended December 31, ~~Adjusted~~2023. ~~operating~~The ~~expenses~~Monthly ~~and~~Operating ~~Adjusted~~Reports ~~EBITDA~~are ~~exclude~~available ~~opioid-related~~for ~~legal~~review ~~expenses~~free of charge at https://restructuring.ra.kroll.com/endo/. The ~~Company~~Monthly ~~believes~~Operating ~~that~~Reports ~~such~~and ~~costs~~other information available on the Kroll website are not ~~indicative~~part of ~~business~~this ~~performance~~Form 8-K and ~~that~~are ~~excluding~~not ~~them~~deemed ~~more~~to ~~accurately~~be ~~reflects~~incorporated by reference in this Form 8-K. Going forward, the ~~Company’s~~Debtors ~~results~~will no longer report the filing of Monthly Operating Reports on a Form 8-K. Investors should review the Kroll website for Monthly Operating Reports and ~~better~~additional ~~enables~~information ~~management~~regarding tothe ~~compare~~Debtors ~~financial~~and ~~results~~their ~~between~~Chapter ~~periods~~11 Cases.

~~Because~~Cautionary ~~adjusted~~Note ~~financial~~Regarding measures exclude the effect of items that will increase or decrease the Company’s reported results of operations, the Company strongly encourages investors to review the Company’s consolidated financial statements and publicly filed reports in their entirety. Investors are also encouraged to review the reconciliation of the nonForward-~~GAAP~~Looking ~~financial~~Statements measures used in the Earnings Release to their most directly comparable GAAP financial measures as included in the Earnings Release. However, the Company does not provide reconciliations of projected non-GAAP financial measures to GAAP financial measures, nor does it provide comparable projected GAAP financial measures for such projected non-GAAP financial measures. The Company is unable to provide such reconciliations without unreasonable efforts due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliations, including adjustments that could be made for asset impairments, contingent consideration adjustments, legal settlements, gains or losses on extinguishment of debt, adjustments to inventory and other charges reflected in the reconciliation of historic numbers, the amount of which could be significant.

~~The~~Certain information in this ~~Item~~Current ~~2.02~~Report on Form 8-K may be considered “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and inany ~~Exhibit~~applicable ~~99.1~~Canadian ~~attached~~securities ~~hereto~~legislation, ~~shall~~including, but not belimited ~~deemed~~to, statements with respect to bethe chapter 11 proceedings, the Company’s emergence from bankruptcy, and any other statements that refer to expected, estimated or anticipated future results or that do not relate solely to historical facts. Statements including words or phrases such as “~~filed~~believe,” ~~for~~“expect,” ~~purposes~~“anticipate,” “intend,” “estimate,” “plan,” “will,” “may,” “look forward,” “guidance,” “future,” “potential” or similar expressions are forward-looking statements. All forward-looking statements in this communication reflect the Company’s current views as of ~~Section~~the 18date of this communication about its plans, intentions, expectations, strategies and prospects, which are based on the ~~Securities~~information ~~Exchange~~currently ~~Act~~available to it and on assumptions it has made. Actual results may differ materially and adversely from current expectations based on a number of ~~1934~~factors, asincluding, ~~amended~~among other things, the following: the timing, impact or ~~otherwise~~results ~~subject~~of any pending or future litigation, investigations, proceedings or claims, including opioid, tax and antitrust related matters; actual or contingent liabilities; settlement discussions or negotiations; the Company’s liquidity, financial performance, cash position and operations; the Company’s strategy; the risks and uncertainties associated with chapter 11 proceedings and the Company’s emergence from bankruptcy; the negative impacts on the Company’s businesses as a result of filing for and operating under chapter 11 protection; the time, terms and ability to consummate the ~~liabilities~~Plan; the adequacy of ~~that~~the ~~section.~~capital ~~The~~resources ~~information~~of ~~contained~~the Company’s businesses and the difficulty in ~~this~~forecasting ~~Item~~the ~~2.02~~liquidity ~~and~~requirements of the operations of the Company’s businesses; the unpredictability of the Company’s financial results while in ~~Exhibit~~chapter ~~99.1~~11 ~~attached~~proceedings; ~~hereto~~the ~~shall~~Company’s ~~not~~ability beto ~~incorporated~~discharge ~~into~~claims ~~any~~in ~~registration~~chapter ~~statement~~11 orproceedings; negotiations with the holders of the Company’s indebtedness and its trade creditors and other ~~document~~significant ~~filed~~creditors; risks and uncertainties with performing under the terms of the Second Amended and Restated Restructuring Support Agreement dated December 28, 2023, by and between the ~~Registrant~~Company and certain of its first lien creditors and any other arrangement with lenders or creditors while in chapter 11 proceedings; the ~~U.S.~~Company’s ~~Securities~~ability to conduct business as usual; the Company’s ability to continue to serve customers, suppliers and ~~Exchange~~other ~~Commission~~business ~~under~~partners at the ~~Securities~~high ~~Act~~level of ~~1933~~service and performance they have come to expect from the Company; the Company’s ability to continue to pay employees, ~~whether~~suppliers ~~made~~and ~~before~~vendors; orthe ~~after~~ability to control costs during chapter 11 proceedings; adverse litigation; the ~~date~~risk ~~hereof~~that the Chapter 11 Cases may be converted to cases under chapter 7 of the Bankruptcy Code; the Company’s ability to secure operating capital; the impact of competition, ~~regardless~~including the loss of ~~any~~exclusivity and generic competition; our ability to satisfy judgments or settlements or pursue appeals including bonding requirements; our ability to adjust to changing market conditions; our ability to attract and retain key personnel; our ability to raise new debt for working capital, capital expenditures, business development, debt service requirements, acquisitions or general ~~incorporation~~corporate ~~language~~or other purposes; our ability to refinance our indebtedness; a significant reduction in ~~such~~our ~~filing,~~short-term ~~except~~or aslong-term ~~shall~~revenues which could cause us to be ~~expressly~~unable ~~set~~to ~~forth~~fund byour ~~specific~~operations ~~reference~~and liquidity needs or repay indebtedness; supply chain interruptions or difficulties; changes in ~~such~~competitive ~~filing.~~or market conditions; changes in legislation or regulatory developments; our ability to obtain and maintain adequate protection for our intellectual property rights; the timing and uncertainty of the results of both the research and development and regulatory processes, including regulatory decisions, product recalls, withdrawals and other unusual items; domestic and foreign health care and cost containment reforms, including government pricing, tax and reimbursement policies; technological advances and patents obtained by competitors; the performance, including the approval, introduction, and consumer and physician acceptance of new products and the continuing acceptance of currently marketed products; our ability to integrate any newly acquired products

~~Item~~ 9into our portfolio and achieve any financial or commercial expectations; the impact that known and unknown side effects may have on market perception and consumer preference for our products; the effectiveness of advertising and other promotional campaigns; the timely and successful implementation of any strategic initiatives; unfavorable publicity regarding the misuse of opioids; the uncertainty associated with the identification of and successful consummation and execution of external corporate development initiatives and strategic partnering transactions; our ability to advance our strategic priorities, develop our product pipeline and continue to develop the market for products; the impact of Irish and other applicable laws; and our ability to obtain and successfully manufacture, maintain and distribute a sufficient supply of products to meet market demand in a timely manner.01 In addition, U. ~~Financial~~S. ~~Statements~~and international economic conditions, including consumer confidence and ~~Exhibits~~debt levels, taxation, changes in interest and currency exchange rates, international relations, capital and credit availability, the status of financial markets and institutions and the impact of continued economic volatility, can materially affect our results. Therefore, the reader is cautioned not to rely on these forward-looking statements. The Company expressly disclaims any intent or obligation to update these forward-looking statements, except as required to do so by law.

Additional information concerning risk factors, including those referenced above, can be found in press releases issued by the Company, as well as the Company’s public periodic filings with the U.S. Securities and Exchange Commission (dthe “SEC”) ~~Exhibits~~ and with securities regulators in Canada, including the discussion under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q or other filings with the SEC. Copies of the Company’s press releases and additional information about the Company are available at www.endo.com or you can contact the Company’s Investor Relations Department at relations.investor@endo.com.

Number			Description
99.1			Press Release
104			Cover Page Interactive Data File (embedded within the Inline XBRL document)

Item 9.01.

Financial Statements and Exhibit

The following exhibits are being filed herewith:


		Exhibit No.		Description

		2.1		Fourth Amended Joint Chapter 11 Plan of Reorganization of Endo International plc and its Affiliated Debtors*

		99.1		Order Confirming the Fourth Amended Joint Chapter 11 Plan of Reorganization of Endo International plc and its Affiliated Debtors

		99.2		Press Release

		104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

*	Schedules (and similar attachments) have been omitted from this filing pursuant to Item 601(a)(5) of Regulation S-K. A copy of any omitted schedule will be furnished to the Securities and Exchange Commission upon request.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.


ENDO INTERNATIONAL PLC

By:		/s/ Matthew J. Maletta
Name:		Matthew J. Maletta
Title:		Executive Vice President, Chief Legal Officer and Company Secretary

Dated: March 625, 2024

Filing Compare · Endo International plc